Everything You Need to Accelerate Evidence Synthesis
A purpose-built platform for systematic and targeted literature reviews, from screening to extraction to reporting, powered by AI you can trust.
How It Works
Three Steps to a Complete Review
EasySLR guides your team through every stage of the review workflow, from initial screening to final data extraction.
Title & Abstract Screening
Import your search results and screen thousands of studies efficiently. AI acts as a copilot, highlighting key terms, suggesting decisions with rationales, and letting your team review at speed without sacrificing accuracy.
Comparative Effectiveness of GLP-1 Receptor Agonists vs DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis
Martinez R, Chen L, Okafor K · Diabetes Care (2024)
Abstract
Background: This systematic review compared the clinical effectiveness of GLP-1 receptor agonists with DPP-4 inhibitors in adults with type 2 diabetes mellitus.
Methods: Thirty-four randomised controlled trials (n=28,042) were included. Eligible studies enrolled adults with type 2 diabetes receiving GLP-1 agonists or DPP-4 inhibitors for ≥12 weeks.
Results: GLP-1 agonists demonstrated superior HbA1c reduction (−0.4%, 95% CI −0.5 to −0.3) and significant weight loss compared with DPP-4 inhibitors.
Include
Relevant
Rationale
Study compares two pharmacological interventions for T2D management with clinical outcomes. Meets population, intervention, and outcome criteria per protocol.
PICOS Extraction
Adults with Type 2 Diabetes
GLP-1 receptor agonists
DPP-4 inhibitors
HbA1c, cardiovascular events
Randomized controlled trial
Full-Text Screening with AI-Enabled PICOS
Upload PDFs and let the platform extract PICOS elements automatically. AI reads full-text articles, identifies eligibility criteria, and provides highlighted evidence so reviewers can confirm or override decisions in context.
Methods
Study Design: This multi-centre randomized controlled trial was conducted across 24 clinical sites in North America and Europe between January 2021 and December 2023.
Participants: We enrolled 1,842 adults aged 30–75 with confirmed type 2 diabetes and inadequate glycemic control (HbA1c 7.5–11.0%) on metformin monotherapy. Key exclusion criteria included renal impairment (eGFR <30), prior GLP-1RA use, and active cardiovascular disease.
Intervention: Participants were randomized 1:1 to semaglutide 1.0 mg weekly or standard of care for 52 weeks. The primary endpoint was change in HbA1c from baseline at week 52.
Include
Relevant
Rationale
RCT comparing GLP-1RA vs standard of care in T2D population with HbA1c and cardiovascular endpoints. Meets all eligibility criteria per protocol.
PICOS Extraction
Adults with Type 2 Diabetes
GLP-1 receptor agonists
Standard of care
HbA1c, weight, cardiovascular events
Randomized controlled trial
Automated Data Extraction
Define your extraction form and let AI pre-populate fields from each study. Every extracted value is linked to its highlighted source in the PDF, making verification fast and auditable.
Effects of Metformin on Glycemic Control in Adults with Type 2 Diabetes: A Multi-Centre Study
Johnson A, Smith B, Patel C, Williams D
Journal of Clinical Endocrinology & Metabolism, Vol 109 (3), 2024
Abstract
Background: This randomized controlled trial1 evaluated the efficacy of metformin monotherapy in newly diagnosed patients with type 2 diabetes across 12 clinical sites in North America and Europe.
Methods: A total of 245 adults aged 18–65 with confirmed type 2 diabetes2 were enrolled and randomized 1:1 to metformin 1 000 mg daily or matched placebo for 12 weeks. The primary endpoint was change in HbA1c from baseline.
Results: The primary endpoint of HbA1c reduction at 12 weeks3 showed significant improvement in the treatment group (−1.2% vs −0.3%, p<0.001). Secondary endpoints including fasting glucose and body weight also favoured metformin.
Study Design
Randomized Controlled Trial
Sample Size
245 participants
Population
Adults 18–65, Type 2 Diabetes
Primary Outcome
HbA1c reduction at 12 wk
Core AI Capabilities
AI That Assists While Humans Decide
Two powerful AI capabilities at the heart of every review, configurable, transparent, and grounded in your data.
Your AI Review Expert
AI-Enhanced Screening
AI functions as both a proactive Copilot during title-abstract and full-text screening, and as an Independent Reviewer alongside human experts. Configure AI involvement from fully manual to AI-assisted. You stay in control.
- Four configurable AI modes
- Published recall of 73–100%
- PICOS extraction from full text
AI-Powered with Source Linking
Automated Data Extraction
Define custom extraction forms and let AI pre-populate fields from each study. Every extracted value is linked to its highlighted source in the PDF, making verification fast and auditable.
- RAG-based extraction from PDFs
- Highlighted source linking
- Custom forms & audit trails
Built for Rigor
Everything Else You Need
From team collaboration to analytics, every tool for auditable evidence synthesis, in one place.
Customizable Workflows
Custom extraction forms, configurable protocols, and AI settings that align with your project requirements.
Team Collaboration
Assign roles, track progress, and work together on a centralized platform with real-time updates.
Full-Text Retrieval
Access the full text of studies instantly with a single click. No manual downloading.
Conflict Resolution
Resolve reviewer disagreements transparently. Manage consensus and maintain review integrity.
Analytics Dashboard
Real-time insights into project progress, reviewer performance, and screening metrics.
Trust & Compliance
Enterprise-Grade Security
Your research data deserves the highest level of protection. We maintain independently audited certifications and established data protection controls so you can focus on your review.
Looking for a Complete Overview?
Learn how EasySLR compares as systematic review software, from pipeline coverage to AI configuration to enterprise security.
Claim your
free project now
No credit card required